| |
|
 |
Q Chip Introduces ReaXT PCR Beads for Molecular
Diagnostics
|
ReaX™ PCR Beads for Molecular Diagnostics
New all-in-one beads pave way for enhanced molecular diagnostics applications
Cardiff, UK, 17 June 2008 – Q Chip Ltd, a leading developer of
microencapsulation solutions, today announced the launch of ReaX™ MDx enhanced
PCR beads for molecular diagnostics. ReaX MDx beads provide a complete assay
in an extremely easy-to-use format with a much simplified workflow compared to
some currently available molecular diagnostics. ReaX MDx eliminate the need
for temperature-controlled logistics – making them particularly suitable for
oncology and infectious disease assays and point-of-care formats.
In 2007, the molecular diagnostics market was worth $2.8 billion worldwide and
growing at 15-20%,* and according to Q Chip CEO Mark Barry, ReaX MDx offers
the first real alternative to lyophilisation. “In addition, the beads meet
other requirements in the fast growing molecular diagnostics market sector,
such as assay simplification combined with reproducible results and we are
currently looking for licensing partners for this exciting technology”.
The new ReaX MDx beads are produced from organic and hydrogel polymers in Q
Chip’s proprietary MicroPlant™ microfluidic device. The MicroPlant produces
beads of extreme uniformity (<2% variability) that encapsulate all the
reagents needed to perform the diagnostic assay. This means that ReaX MDx
assays require minimal user input, time and skill level giving results that
are accurate and reproducible every time, no matter where or by whom the assay
is performed. The MicroPlant production technology also offers significant
benefits compared to conventional microencapsulation processes, such as
ultra-low wastage, uniform dosing and morphology, and low process costs.
* Source: Insight Pharma Reports
www.q-chip.com
- ENDS -
NOTES TO EDITORS.
Q Chip Ltd, a Life Science Company headquartered in Cardiff, develops
precision microsphere based packaging products for the pharmaceutical, medical
device and diagnostic markets. Q Chip’s primary investors are The Sustainable
Technology Partnership, E-Synergy’s Early Growth Fund, The Forum of The
Future, Fusion Cardiff Limited, Finance Wales and Jon Moulton.
-end-
Product enquiries:
Q Chip Limited
Nanette Bartram, Product Manager +44 (0)29 2068 2092
Email: nanette.bartram@q-chip.com
Media enquiries
Alto Marketing Limited
Nicki Muir, Science Writer/PR Executive +44 (0)1489 557672
Email: nickim@alto-marketing.com
